Aims: Resistin, a newly discovered adipokine, is thought to play a key role in the regulation of insulin resistance. The objectives of this study were to develop a nomogram of maternal plasma concentrations of resistin from 11 weeks of gestation to term and to determine whether resistin concentrations differ between normal and overweight pregnant women. Methods: In this cross-sectional study, plasma concentrations of resistin were determined in normal pregnant women of normal body mass index (BMI 18.5-24.9; ns261), overweight pregnant women (BMI G25; ns140), and non-pregnant women of normal BMI (ns40). Blood samples were collected once from each woman between the first trimester and term. Percentiles for resistin concentration were determined for five prespecified windows of gestational age. Plasma resistin concentration was determined by immunoassay. Nonparametric statistics were used for analysis. Results: The median maternal plasma concentration of resistin between 11 to 14 weeks of gestation in women of normal weight was significantly higher than non-pregnant women; the plasma concentration of resistin increased with gestational age. Conclusions: Normal pregnant women have a higher median plasma concentration of resistin than non-pregnant women and the concentration of this adipokine increases with advancing gestation. Alterations in the maternal plasma concentration of resistin during pregnancy could contribute to metabolic changes of pregnancy.
Introduction
Pregnancy is a unique state characterized by physiological insulin resistance that resolves postpartum w11- 13, 15, 16, 28, 54, 57, 60, 74, 85, 92x . However, the mechanisms responsible for insulin resistance are not well understood. By increasing glucose availability, insulin resistance may facilitate delivery of energy to the fetus w55, 74, 84x. Insulin resistance during pregnancy is commonly attributed to the increased concentration of several placental hormones in maternal serum. Evidence in support of this hypothesis includes: (1) infusion of human placental lactogen (hPL), a hormone produced abundantly by the placenta, can induce metabolic changes in non-pregnant subjects w44, 87x; (2) similar effects have been observed after treatment with progesterone w8, 45x, estrogen w76x or glucocorticosteroids w7, 44x; (3) insulin action on adipocytes is impaired after in vitro exposure to progesterone, cortisol, prolactin, and human placental lactogen w86x; and (4) insulin resistance during pregnancy rises as a function of increasing plasma concentrations of placental hormone secretion.
The conventional view is that the placenta plays a key role in the mechanisms responsible for insulin resistance in pregnancy. However, the role of adipose tissue in the pathophysiology of insulin resistance has been a subject of interest w33, 39, 42, 43, 63, 69, 82, 93, 97x . Adipose tissue can exert its effects by several mechanisms, including the secretion of bioactive peptides. These bioactive substances, collectively termed adipokines, include leptin w26, 29, 30x, adiponectin w2, 9, 41, 64x, tumor necrosis factor a w38, 98x, interleukin-6 w100, 101x, C-reactive protein w10, 70x, resistin w6, 37, 49, 94x and others w56, 82, 83x. Recently, adipokines have been implicated in the regulation of insulin resistance during pregnancy. Serum concentrations of tumor necrosis factor-a w52, 65x, adiponectin w18, 61, 65, 81x, leptin and C-reactive protein w65x correlate with indices of insulin resistance during pregnancy.
Resistin is a novel adipokine with a molecular weight of 12.5 kDa w37, 49, 66, 77, 94, 104x . In mice, the synthesis of resistin is restricted to adipocytes. However, in humans, adipocytes, muscle w56x, pancreatic islets w68x, mononuclear cells w47x and placenta w34, 58, 107x can synthesize this protein. Several lines of evidence support the association between resistin and insulin resistance: (1) in mice, obesity is associated with increased plasma resistin concentrations w77x; (2) resistin mRNA expression in adipocytes is low during fasting but increases significantly when fasting mice are refed with a high carbohydrate diet (25-fold) or treated with insulin (23-fold) w49x; (3) treatment of normal mice with recombinant resistin impairs glucose tolerance and insulin action; (4) administration of anti-resistin antibodies potentiates insulinstimulated glucose uptake in mice with diet-induced obesity w94x; (5) in vitro neutralization of resistin results in enhanced insulin-stimulated glucose uptake by adipocytes w94x; and (6) in humans, plasma resistin concentration correlates with insulin resistance indices and obesity w89, 95x.
The objective of this study was to generate a nomogram of maternal plasma concentrations of resistin during pregnancy by determining concentrations of this hormone during first, second and third trimesters of pregnancy. In addition, we sought to determine whether BMI affects the maternal plasma concentrations of resistin.
Materials and methods

Study design and population
This retrospective, cross-sectional study compared maternal plasma resistin concentrations among pregnant women of normal weight (ns261), overweight pregnant women (ns140) and non-pregnant women (ns40). Non-pregnant women were included in the study if they had no chronic disease, did not use oral contraception, and had a body mass index (BMI) -25 kg/m 2 . The inclusion criteria for the pregnant group were: (1) singleton pregnancy; (2) no prior diabetes mellitus or other chronic diseases; (3) no obstetrical, maternal, or fetal complications; (4) a normal plasma glucose concentration in the first trimester; (5) a normal oral glucose tolerance test in the third trimester; and (6) delivery at term of a neonate with birthweight appropriate for gestational age. The first trimester BMI was calculated with the following formula: BMIsweight (kg)/height (m 2 ). A normal BMI was defined when the values were between 18.5 and 24.9. A patient was considered overweight if the BMI was G25 w24x. Written informed consent was obtained from all participants. The study was approved by the Institutional Review Board. Many of the samples from these patients have been employed to study the biology of inflammation, hemostasis, angiogenesis regulation, and growth factor concentrations in non-pregnant women, normal pregnant women and those with pregnancy complications.
Blood collection and resistin immunoassay
Blood samples from non-pregnant women were obtained during the secretory phase of the menstrual cycle, and from pregnant women at 11-14 weeks, 15-18 weeks, 27-30 weeks, or )37 weeks of gestation. These samples were collected into vials containing ethylenediamine tetra-acetic acid and centrifuged for 10 min at 48C. Plasma was stored at -708C until analysis. Plasma resistin concentrations were determined with Human Resistin ELISA (LINCO Research Inc, St Charles, MO, USA), following the recommendations of the manufacturer. The sensitivity of the assay was 0.095 ng/mL and the inter-and intra-assay coefficients of variation were 5.9% and 5.8%, respectively.
Statistical analysis
Normality of the data was tested using the Shapiro-Wilk test. The plasma resistin concentrations were not normally distributed. Thus, non-parametric tests were used in the data analysis. The relationship between maternal plasma resistin concentration and gestational age was examined using the Spearman rank test. Comparisons of the median resistin concentration among groups were performed using the Kruskal-Wallis test. Post hoc analyses were done with Mann-Whitney U-test, and Bonferroni adjustment was applied for multiple comparisons. Analysis of covariance (ANCOVA) was performed to control for confounding factors that could affect plasma resistin concentrations during pregnancy. Table 1 displays the demographic characteristics and plasma resistin concentrations of the three study groups. No significant differences in age, weight, and BMI were observed between pregnant women of normal weight and non-pregnant women. There was a higher proportion of nulliparous women in the non-pregnant group (P-0.05).
Results
Resistin was detected in the plasma of all subjects. Pregnant women of normal weight had a significantly higher median plasma resistin concentration than did non-pregnant women (Table 1) . These results did not change after adjusting for parity (non-pregnant nulliparous median: 10.2 ng/mL, range: 5-16 vs. pregnant nulliparous median: 12.5 ng/mL, range: 5-40; Ps0.04; and non-pregnant multiparas median: 9.9 ng/mL, range: 6.3-24.2 vs. pregnant multiparas median: 13.3 ng/mL, range: 6-81.4; Ps0.02). Plasma resistin concentrations remained invariable before term (11-14 weeks vs. 15-18 weeks, Ps0.18; 11-14 weeks vs. 27-30 weeks, Ps0.44; 15-18 weeks vs. 27-30 weeks, Ps0.66). In contrast, a significant increase of plasma resistin concentrations was observed at term (**P-0.05 for each comparison. All P-values were adjusted for multiple comparisons).
Pregnant women between 11 and 14 weeks of gestation had significantly higher plasma concentrations of resistin than did non-pregnant women (Ps0.003; Figure  1 ). A significant positive correlation was observed between plasma resistin concentrations and gestational age (rs0.22; P-0.01). Maternal plasma concentrations of resistin at term were significantly higher than those of patients in the first (11-14 weeks), second (15-18 weeks) or early third (27-30 weeks) trimester. In contrast, there were no significant differences in the resistin concentrations among the first, second, and early third trimester groups (Figure 2) .
In order to examine the effects of confounding factors that may affect maternal plasma concentrations of resistin, analysis of covariance was applied, including maternal age, parity, BMI during first trimester, and gestational age (categorized into -37 and G37 weeks). This model showed that BMI did not contribute to the maternal plasma concentrations of resistin during pregnancy. Indeed, there were no significant differences in plasma resistin concentrations between normal weight and overweight women at different gestational ages (Figure 3) . 
Discussion
Principal findings of this study
(1) Pregnant women of normal weight had a significantly higher median plasma resistin concentration compared to non-pregnant women; (2) plasma resistin concentra-
Figure 3
Plasma resistin concentrations of normal-weight (BMI 18.5-24.9) and overweight (BMI G25) pregnant women. No significant differences were observed in the plasma resistin concentrations between both groups at different gestational ages. tions change as a function of gestational age; (3) maternal plasma concentrations of resistin were significantly higher at term than in the first, second, or early third trimester; and (4) a nomogram for maternal plasma resistin concentration is presented.
Pregnancy as a forme fruste of the metabolic syndrome
A ''physiological adaptation'' of normal pregnancy includes insulin resistance w11-13, 28, 60, 74, 85, 92x, hyperlipidemia w17, 22, 73, 91x, increased weight and fat deposition w14, 25, 40, 51, 75x. These changes are considered components of the metabolic syndrome w1x, although physiological alterations during pregnancy do not necessarily meet the threshold values for the definition of the metabolic syndrome. The profound metabolic changes are thought to be necessary for meeting the energy demands of the rapidly growing fetus and placenta. Insulin resistance is the most studied metabolic change during pregnancy. This is probably due to the fact that it stands out as a potential causative factor for other metabolic changes w1x, or to the significant clinical consequences of gestational diabetes. While there is ample literature regarding the changes in glucose and insulin metabolism during gestation, data regarding the specific mechanisms underlying these changes are scant. Placental hormones such as hPL are thought to be the main factors in inducing gestational insulin resistance. This hypothesis was supported by the finding that placental hormones have diabetogenic effects both in vitro w86x and in vivo w7, 8, 44, 45, 76, 87x . In addition, insulin resistance rises with the increased maternal serum concentrations of multiple placental hormones and resolves soon after delivery.
Adipose tissue, adipokines and insulin resistance in pregnancy
Pregnancy is characterized by insulin resistance, traditionally attributed to the effect of placental hormones w7, 8, 44, 45, 62, 76, 86, 87x . A single mechanism is unlikely to explain the link between pregnancy and insulin resistance. A large body of evidence has supported the role of adipose tissue in the induction and regulation of insulin resistance in non-pregnant and pregnant subjects. Indeed, during the last decade, the notion of adipose tissue as an important endocrine organ has emerged w23, 43, 83x, and the role of adipocytes and other cellular components of adipose tissue has been strengthened. Moreover, adipokines, which are adipocyte-derived hormones, have been implicated in the regulation of insulin resistance during pregnancy. Several findings support the role of adipokines in the physiology and pathophysiology of insulin resistance during pregnancy: (1) maternal serum concentrations of tumor necrosis factor-a w52, 65x, adiponectin w18, 61, 65, 81x, leptin and C-reactive protein w65x are correlated with clinical indices of insulin resistance; (2) in the third trimester, insulin resistance in obese women increased by 40% w90x, but only 25% in non-obese women w15x; and (3) patients with gestational diabetes have increased maternal serum concentrations of tumor necrosis factor-a w4, 50, 52, 65, 103x, C-reactive protein w65x, hyperleptinemia w4, 48, 52, 65x, and hypoadiponectinemia w4, 50, 79, 96, 102, 104, 105, 107x. The insulin resistance during pregnancy is accompanied by a remarkable increase in adipose tissue deposits, suggesting that adipose tissue has a role in the induction and regulation of gestational insulin resistance. Our findings of elevated plasma resistin concentrations during pregnancy and further increases in the concentrations at term support the association between adipokines and insulin resistance during pregnancy.
Resistin and insulin resistance in non-pregnant subjects
Resistin is a newly-discovered adipokine w37, 49, 66, 77, 94, 104x. In vivo studies in rodents confirmed the exclusive production of this hormone by adipose tissue. However, studies in humans have revealed that resistin is not tissue-specific and that it can be produced by muscle w56x, pancreatic islets w68x, mononuclear cells w47x and placenta w34, 58, 107x. Preliminary studies (in vitro and in animals) suggest that resistin has a role in insulin resistance and that this adipokine could be the link between obesity and insulin resistance w5, 94x. Indeed, exposure of adipocytes to resistin impairs insulin-stimulated glucose uptake, while anti-resistin antibodies prevent this effect w94x. Hyper-resistinemia is a characteristic of obese mice, and treatment with resistin induces insulin resistance in mice with diet-induced insulin resistance, while immunoneutralization of resistin reduces hyperglycemia w94x. Finally, resistin induces hepatic insulin resistance in rats w78x.
There is controversy in the literature regarding the association between resistin, insulin resistance and obesity in humans. Hyper-resistinemia has been documented in subjects with HIV lipodystrophy and hyperinsulinemia w46x, patients on chronic haemodialysis w27x and subjects with Prader-Willi syndrome w71x, all conditions closely linked to insulin resistance. Moreover, higher plasma concentrations of resistin have been reported in obese individuals compared to lean subjects w32x and in patients with diabetes compared to normal subjects w31, 106x. However, other investigators have not found an association between resistin and insulin resistance or obesity w3, 35, 59, 80, 88x.
Resistin and insulin resistance in human pregnancy
Only a handful of studies have investigated serum concentrations of resistin in human pregnancy w19-21, 34, 36, 72, 99, 107x. Our finding of higher plasma resistin concentrations in pregnant women compared to nonpregnant subjects are consistent with reports by Yura et al. w107x, Cortelazzi et al. w21x and Palik et al. w72x . However, Chen et al. reported that differences between serum resistin concentrations of non-pregnant and pregnant women are significant only in the third trimester w19x. The finding that BMI does not contribute to the plasma concentrations of resistin during pregnancy is in agreement with a study by Hendler et al. w36x in which maternal serum resistin is not correlated with BMI. Herein, we report a positive correlation between maternal plasma resistin and gestational age, which contrasts with a previous report by Cortelazzi et al. w21x. However, differences in study design and sample size may contribute to the differences among studies. In particular, our study was conducted using a relatively large number of patients at gestational ages ranging from the first trimester to term, and with different BMIs.
Why do maternal serum/plasma concentrations of resistin increase during pregnancy?
Our results indicate that pregnancy is associated with higher plasma concentrations of resistin than in the nonpregnant state and that a further elevation is observed during the third trimester. Several explanations can account for this finding:
1. Insulin resistance during pregnancy: Maternal serum resistin was associated with surrogate indices of insulin resistance in patients with gestational diabetes w72x. The data obtained in the present study do not allow us to discern cause-and-effect relationships; however, the possibility that alterations in maternal plasma concentrations of resistin during pregnancy have a role in the regulation of the metabolic changes with advancing gestation should be considered. 2. Increased fat deposition during pregnancy: Pregnancy is characterized not only by insulin resistance but also by a remarkable increase in adipose tissue deposits. Given that resistin is produced by adipose tissue, it is plausible that plasma resistin is elevated simply due to this increase in fat mass. 3. Increased visceral fat depot during pregnancy: Some data support an increase in intra-abdominal fat during pregnancy w51x. Of note, visceral fat amount is significantly higher during the third trimester, when maternal serum resistin concentrations are at their peak. These findings are consistent with the report by McTernan et al., which demonstrated higher resistin mRNA expression w67x and protein w66x in visceral fat than in peripheral fat in the thigh and the breast. Taken together, the regional alteration in fat distribution during pregnancy may be related to the increase in maternal plasma resistin. 4. Secretion by the placenta: The human placenta has been reported to be a site of resistin production w34, 58, 107x. Resistin gene expression in term placentas is higher than that in first trimester w107x. The hypothesis that the placenta is a major contributor to maternal plasma resistin is in line with our findings of higher plasma concentrations of resistin in the pregnant state, the dramatic increase observed during the third trimester, as well as the lack of correlation with maternal BMI.
Conclusions
In summary, the results presented herein indicate that pregnancy is associated with higher plasma concentra- 
